Understanding of the Underlying Mechanisms of Target-Independent Uptake and Toxicity
With 4 approved agents, antibody-drug conjugates or ADC have shown to be a very promising class of therapeutics.
While the concept of ADCs is not...
In the War Against Brain Cancer, Accelerated Clinical Trials Are a Crucial Strategy
More than 1.4 million people live with malignant brain tumors. Glioblastoma – the cancer that killed Senators John McCain and Ted Kennedy – is...
How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall?
In the aftermath of the fall of renowned breast cancer researcher Jose Baselga, MD, PhD, following revelations last month of his failure to disclose...
Benefitting from the Worldwide Supply Chain in the development of Antibody-drug Conjugates
Timing is everything.
Just over a decade ago, the pharmaceutical industry and R&D in China was dominated by generics and plagued with insufficient technical capacity...
Eric Rosenthal Reports | A Personal Remembrance of Two Giants of Oncology: Jim...
James F. Holland, MD, one of the pioneers of combination chemotherapy and cancer cooperative group research, died at the age of 92 on March...
PepTalk: The Protein Science Week – New Horizons, New Goals
This year PepTalk: The Protein Science Week, one of the largest annual gatherings of protein science researchers in the world - now in its...
Moving Ahead: More ADC Progressing Through the Clinic and Beyond Oncology and Hematology
This week from September 20-22, 2017, the 8th World ADC, the industry’s leading forum, discussing the latest developments and breakthroughs in antibody-drug conjugates, will...
What Governments Can Do To Address Cancer
While much work remains to find a cure for cancer – the good news is we know that many forms of cancer are preventable....
A Call to Action: Submit Your Expertise
Valuable lessons learned from both approved antibody-drug conjugates (brentuximab vedotin /Adcetris®; Seattle Genetics approved in 2011 and ado-trastuzumab emtansine or T-DM-1/Kadcyla® approved in 2013)...
More ADC Targets Emerging, But They are Taking Longer to Commercialize
The Antibody-drug Conjugate (ADC) field remains an exciting area and Piramal is privileged to be in a great location to see the current progress...
